Gilles Montalescot, Alban Redheuil, Flavien Vincent, Steffen Desch, Mauro De Benedictis, Hélène Eltchaninoff, Dietmar Trenk, Jean-Michel Serfaty, Etienne Charpentier, Khaoula Bouazizi, Mikael Prigent, Paul Guedeney, Tomy Salloum, Sergio Berti, Angel Cequier, Thierry Lefèvre, Pascal Leprince, Johanne Silvain, Eric Van Belle, Franz-Josef Neumann, Jean-Jacques Portal, Eric Vicaut, Jean-Philippe Collet
BACKGROUND: Subclinical obstructive valve thrombosis after transcatheter aortic valve replacement (TAVR) is of uncertain frequency and clinical impact. OBJECTIVES: The aim of this study was to determine the effects of apixaban vs standard of care on post-TAVR valve thrombosis detected by 4-dimensional (4D) computed tomography. METHODS: The randomized ATLANTIS (Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events After Trans-Aortic Valve Implantation for Aortic Stenosis) trial demonstrated that apixaban 5 mg twice daily was not superior to standard of care (vitamin K antagonists or antiplatelet therapy) after successful TAVR and was associated with similar safety but with more noncardiovascular deaths...
September 26, 2022: JACC. Cardiovascular Interventions